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The liver synthesizes circulating coagulation proteins needed
for the complex hemostatic process that operates in vivo to
stop bleeding and prevent the unwanted thrombin genera-
tion and ﬁbrin deposition. As a consequence, liver dysfunc-
tion is invariably associated with decreased levels of plasma
coagulation proteins (except for factor VIII and von Wille-
brand factor, which are increased).1 These observations have
been taken over the years as evidence to explain the abnor-
malities of traditional coagulation tests such as the prothrom-
bin time (PT) and activated partial thromboplastin time
(aPTT) that are typically observed in patients with cirrhosis,
but also to explain the bleeding events that are occasionally
associated with this condition. While the ﬁrst is reasonable,
the second needs comments and reconsideration. This article
aims at discussing observations provided by the most recent
literature that makes the long-lasting belief of chronic liver
disease as the prototype of the acquired hemorrhagic coagu-
lopathies to be reconsidered and an old paradigm to be
dismantled. This change of paradigm will have profound
practical impact on how the complex hemostatic dysfunction
is managed in this category of patients. The key points and
messages of the article are summarized in ►Table 1.
Hemostasis in vivo is a tightly regulated mechanism
responsible for the conversion of ﬁbrinogen into ﬁbrin and
its subsequent degradation. The entire mechanism can be
dissected into the following three parts: platelet–vessel wall
interaction (also known as primary hemostasis), coagulation






Abstract Cirrhosis presents with decreased procoagulant factors as a consequence of the
impaired synthetic capacity of the liver. This was taken as evidence to explain the
abnormalities of the coagulation tests prothrombin time (PT) and activated partial
thromboplastin time (aPTT) and the bleeding events that occur in these patients. It was
for long time (and probably is still) common practice to test patients with the PT and to
treat those with predeﬁned (but arbitrary) cutoff values with plasma or prohemostatic
agents to prevent or stop bleeding. However, anticoagulant factors that contrast the
procoagulants are also decreased in cirrhosis. It was therefore postulated that the
coagulation balance (i.e., the net result between the action of pro- and anticoagulants)
is somewhat rebalanced. Subsequent studies supported this view showing that plasma
from cirrhotic patients generates normal amounts of thrombin. In addition, primary
hemostasis (i.e., platelet–vessel wall interaction) is rebalanced notwithstanding cirrho-
sis present with thrombocytopenia. It was shown that increased levels of the adhesive
protein von Willebrand factor (a typical feature of cirrhosis) compensate for the low
number (function) of platelets. The earlier considerations have been instrumental to
help dismantle the old paradigms of cirrhosis as the epitome of the acquired
hemorrhagic coagulopathies and the traditional coagulation tests PT and aPTT as
suitable predictors of bleeding risk. The demise of the old paradigms and the rise of the
new one may have important practical implications for the management of patients
with cirrhosis and will be discussed in this chapter.
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degradation (i.e., ﬁbrinolysis). In the following paragraphs,
two of the three mechanisms will be revisited. Fibrinolysis
will be discussed in another chapter of this journal.
Platelet–Vessel Wall Interaction
Platelets contribute to the hemostatic process by adhesion to
the subendothelial matrix at the site of vessel wall injury by
means of the adhesive multimeric protein von Willebrand
factor. On adhesion, they undergo activation, shape change,
and secretion that ultimately lead to aggregation. In a subse-
quent step, they express the negatively charged phospholipid
phosphatidylserine on their surface, which acts as a receptor
for the vitamin K–dependent coagulation factors needed to
speed up thrombin generation, ultimately leading to the
conversion of ﬁbrinogen into ﬁbrin. As a consequence of
the variable thrombocytopenia that is associated with cirrho-
sis,2 it is generally believed that the function of platelets in
this setting is hampered, and that platelet counts should be
restored to prevent or stop bleeding before or during invasive
procedures.3 This concept is based on biological plausibility
and much less on evidence stemming from clinical trials.
Furthermore, neither the platelet count that would indicate
the need for infusion nor the target platelet numbers are
known. Finally, hemostatic tests that are able to reliably guide
transfusion are not widely available and the signiﬁcance of
their results are not precisely known.
Recently, it was shown that patients with cirrhosis display
platelet adhesion in a ﬂowing system (mimicking the con-
ditions that occur in vivo) similar to those of healthy subjects,
despite these patients being thrombocytopenic. Apparently,
high levels of von Willebrand factor, typically observed in
these patients, compensate for the lownumber (and function)
of platelets.4 More recently, it was demonstrated that also
thrombin generation in platelet-rich plasma in cirrhosis is
normal if platelet numbers are higher than 60  109/L.5 The
earlier observations can be taken as indications that patients
with cirrhosis do not need an indiscriminate platelet trans-
fusion unless they are severely thrombocytopenic. A recent
study demonstrated that infusion of one single adult platelet
unit was not able to substantially increase platelet numbers of
patients with cirrhosis with preinfusion values of 50  109/L
or less.6 Moreover, neither thrombin generation in platelet-
rich plasma nor thromboelastometry parameters in whole
blood were signiﬁcantly altered by the transfusion.6 These
observations seem to indicate that for a substantial platelet
Table 1 Hemostatic dysfunction in chronic liver diseasea
Platelet count Decreased2
von Willebrand factor Increased4
(Primary) hemostasis balance Restored because of the increased levels of the adhesive protein von Willebrand
factor4





Coagulation balance Restored because of the concomitant deﬁciency of pro- and anticoagulants10
PT and aPTT Prolonged, but they do not represent the mechanism of coagulation operating
in vivo.17 They are responsive to the procoagulants, but much less to the
anticoagulants. Their abnormalities are poorly associated with bleeding12
The balance of hemostasis in cirrhosis Although restored is unstable because of the relative deﬁcit of pro- and
anticoagulants as well as thrombocytopenia. It may tip toward hemorrhage or
thrombosis, depending on the circumstantial risk factors or conditions
Conditions associated with cirrhosis that
may explain bleeding
Portal hypertension, bacterial infections, endothelial dysfunction, renal failure
Thrombosis in cirrhosis Patients with cirrhosis are not fully protected from venous thromboembolism
(VTE).24 Their relative risk for VTE has been estimated two times higher than that
of noncirrhotic patients.25
Consequences stemming from the
aforementioned considerations
• PT and aPTTshould not be used as predictors of bleeding or to guide transfusion
with fresh frozen plasma or procoagulant agents.
• Infusion of plasma or procoagulant agents is poorly effective in controlling
bleeding13–16 and may occasionally result in adverse events. Their
indiscriminate use should be discouraged.
• The same considerations apply to platelet transfusion or treatment with
agonists of the thrombopoietin receptors7,8
• Patients with cirrhosis are not auto-anticoagulated and deserve therefore to be
treated with anticoagulants to treat or prevent thrombosis.27
Abbreviations: aPTT, activated partial thromboplastin time; PT, prothrombin time.
aKey points only; see the text for details.
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increasemultiple transfusions are required. As an alternative,
an increased platelet count could be obtained with treatment
with agonists of the thrombopoietin receptors such as
eltrombopag.6 It should, however, be realized that a recent
clinical trial on the efﬁcacy of eltrombopag to increase the
platelets count in patients with cirrhosis undergoing invasive
procedures, was prematurely terminated because of an
excessive rate of thrombotic events in the eltrombopag arm
of the study.7 All in all, the earlier observations indicate that
decision on whether platelets should be increased in individ-
ual patients should not be made indiscriminately, but after
careful consideration of the risk/beneﬁt ratio.8
Coagulation
As aforementioned, coagulation is a tightly regulated mech-
anism in which the procoagulant drivers (i.e., procoagulant
proteins) speed up thrombin generation to convert ﬁbrino-
gen into ﬁbrin. The procoagulant drivers are opposed in vivo
by their anticoagulant counterparts, that is, the naturally
occurring anticoagulants antithrombin, protein C, protein S,
and the tissue factor pathway inhibitor. Under physiological
conditions, the two drivers oppose each other and prevent
the unwanted thrombin generation and ﬁbrin deposition.
Like the procoagulants, the anticoagulants are also synthe-
sized by the liver and consequently the pro- and antico-
agulants are concomitantly decreased in patients with
cirrhosis. The pathophysiological signiﬁcance of this simple
observation escaped the attention of clinicians for many
years and very few realized that there might be a rebalanced
coagulation in patients with chronic liver disease.9 In 2005,
support to the earlier postulate was provided by an in vitro
study showing that thrombin generation in patients with
cirrhosis is essentially normal if investigated by global tests
responsive to both the pro- and anticoagulants.10 Thrombin
generation tests can be made responsive to both pro- and
anticoagulants by the addition of thrombomodulin, thus
allowing full activation of the protein C anticoagulant sys-
tem.11 Thrombomodulin is located on endothelial cells and
much less in plasma.
The PT and aPTT are coagulation tests with clot formation
as an endpoint that occur few seconds after the activation of
coagulation. Importantly, they are performed using plasma in
the absence of thrombomodulin. All these considerations
lead to the logical conclusion that PT and aPTT are responsive
to the procoagulant drivers (they are in fact perfectly suitable
to diagnose hemophilia and allied disorders), butmuch less to
the anticoagulant drivers (they are in fact normal in patient
with congenital deﬁciency of the naturally occurring anti-
coagulants). This explains the poor correlation between
bleeding and the abnormality of these tests that has been
observed but not underscored for many years in patientswith
cirrhosis.12 This notwithstanding, the use of PT and aPTT as
predictors of bleeding is still common practice in cirrhosis,
and patients with test results earlier predeﬁned (but arbi-
trary) cutoff values are frequently given prophylaxis with
fresh frozen plasma or prohemostatic agents before invasive
procedures.
Recently, clinical trials comparing usual care versus infu-
sion of recombinant activated factor VII (NovoSeven, Novo
Nordisk, Bagsvaerd, Denmark; one of the most potent pro-
hemostatic agents) have been performed in patients with
cirrhosis with active variceal bleeding13,14 (one of the most
common and severe bleeding events in cirrhosis) or in
patients with cirrhosis undergoing hepatectomy or liver
transplant surgery.15,16 Results of these trials showed that
NovoSeven, while effective in normalizing the PT,13 had no
effect on bleeding. As a matter of fact, if thrombin generation
in cirrhosis is normal, it does not need to be increased by
infusion of procoagulant agents. As an alternative to Novo
Seven, fresh frozen plasma is often used as prophylaxis in
patients with cirrhosis. However, no data from controlled
clinical trials are available to determine the efﬁcacy/safety of
infusion of fresh frozen plasma in patients with cirrhosis.
Recently, plasma from patients with compensated cirrho-
sis has been spiked in vitro with appropriate amounts of a
pooled normal plasma in a patient-to-normal plasma ratio
mimicking an infusion of 15mL/kg fresh frozen plasma17 (i.e.,
the dose commonly used for patient treatment). Mixtures
were tested for PT, aPTT, and thrombin generation. Results
demonstrated that the PT and aPTT that were abnormally
prolonged in the majority of patient plasmas before mixing,
were shortened to a considerable degree, but they did not
normalize on mixing with the pooled normal plasma.17
Conversely, thrombin generation in the presence of throm-
bomodulin that was within the normal range in all plasmas
before mixing, remained unchanged after mixing.16 These
results seriously question the validity of the PT as a test to
guide transfusion of fresh frozen plasma in the setting of
cirrhosis.
Although randomized controlled trials with clinical end-
points are needed to substantiate the earlier hypothesis, it is
likely that fresh frozen plasma at the dose commonly
employed (i.e., 15 mL/kg) can hardly be effective in increasing
thrombin generation. Nevertheless, it cannot be excluded
that plasma infusion at higher doses, by increasing both the
pro- and anticoagulant drivers, could be effective in stabi-
lizing the (the rather unstable) balance of coagulation in
these patients. However, this can be likely achieved only by
infusing such an amount of plasma resulting in ﬂuid
overload and exacerbation of portal hypertension and
bleeding. The earlier observations once again support the
concept that the PT and aPTT are in vitro tests not suitable
to evaluate the coagulation derangement occurring in
cirrhosis (and perhaps in other acquired hemorrhagic
coagulopathies)18 and should therefore not be used as
predictors of bleeding in this setting.
On the contrary, the PT test still maintains its validity as a
prognostic index to judge the severity of liver dysfunction. It
is incorporated into the equation deﬁning the model of end-
stage liver disease (MELD) score that is used to prognosticate
survival and prioritize patients for liver transplantation. PT
results can be expressed as ratio (patient-to-normal clotting
times), the higher the ratio the longer the PT or as interna-
tional normalized ratio (INR). The latter expression is essen-
tially the PT ratio corrected for a sensitivity index
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(international sensitivity index, ISI) relative to a WHO stan-
dard thromboplastin (i.e., INR ¼ [PTpatient/PTnormal]ISI).19
The INR has been developed to be used for patients on
vitamin K antagonists (VKA). The coagulation defect induced
by VKA on the same patient is judged differently by laborato-
ries using different commercial thromboplastins when the
results are expressed as PT ratio. However, the INR proved
effective in better harmonizing the results, thus giving pa-
tients the opportunity to move freely from one laboratory to
another and clinicians to use “universal therapeutic intervals”
stemming from large clinical trials within which to maintain
their patients. The development and implementation of the
INR (also endorsed by WHO) represents an example of
ingenuity and a landmark in the history of anticoagulation.
Unfortunately, very few realized that the INR was designed to
harmonize PT results for patients on VKA and that its appli-
cation in other conditionswould have been questionable. As a
matter of fact, the ISI required to convert PT ratios into INR is
derived using plasma from patients on VKA.19 The coagul-
opathy induced by other clinical conditions (such as cirrhosis)
may be different from that induced by VKA, thus making the
ISI invalid, unless it is speciﬁcally determined for these
conditions. This concept was not underscored for many
years,20 and the MELD score was developed and validated
by using the INR to express PT results in patients with
cirrhosis.21 The logical consequence is that PT results be-
tween laboratories are not harmonized and any given patient
awaiting liver transplantation might receive a different PT
(and therefore MELD) result depending on the thromboplas-
tin used for testing. This situation might considerably modify
the order of priority in the waiting list for transplantation18
and should therefore be urgently corrected. Proposals for a
modiﬁed standardization model using plasma from patients
with cirrhosis to calculate the ISI for commercial thrombo-
plastin and the INR (called INRliver as opposed to INRVKA) have
been made by two independent groups and wait to be
implemented.22,23
Hypercoagulability and Cirrhosis
As mentioned, hemostasis in cirrhosis is rebalanced, but the
balance between the pro- and anticoagulant drivers is not
that stable as in healthy subjects. While in healthy subjects
there is a large excess of pro- and anticoagulants as well as
platelets that stabilize the system, in patients with cirrhosis,
there is a relative deﬁcit in all of them. Therefore, it is logical
to assume that the hemostatic balance is unstable andmay tip
toward hemorrhage or thrombosis depending on circumstan-
tial risk factors and/or other conditions that are associated
with cirrhosis (i.e., portal hypertension, bacterial infections,
endothelial dysfunction, renal failure, etc.). As amatter of fact,
patients with cirrhosis may present with thrombotic events,
thus questioning the old belief that these patients are auto-
anticoagulated because of their hemostatic derangement. For
instance, it was recognized many years ago that hospitalized
patients with cirrhosis are not fully protected from venous
thrombosis, including deep vein thrombosis and pulmonary
embolism.24 In addition, a nationwide population-based
case–control study performed in a large population of
patients with liver disease and control subjects showed
that these patients are cumulatively exposed to a relative
risk of venous thromboembolism that amounted to nearly
two times if compared with that of the control population.25
Furthermore, portal vein thrombosis (PVT) is considered as
one of the most severe complications of cirrhosis resulting in
portal hypertension and its complications such as variceal
bleeding, thrombocytopenia, and splenomegaly.26 The fre-
quencyof PVT in patientswith cirrhosis has been estimated to
vary from approximately 1% among patients with compen-
sated cirrhosis but 8 to 25% among those who are candidates
for liver transplantation.26 Although PVT is not a contraindi-
cation for transplantation, it may worsen posttransplant
prognosis, making patients awaiting transplantation candi-
dates for primary prevention.
Recently, a randomized controlled trial showed that
patients with end-stage chronic liver disease, who received
daily prophylactic doses of low-molecular-weight heparin
(LMWH) had less PVT and no more hemorrhagic events than
those randomized to the usual care. In addition, the study
showed that LMWH was effective in slowing the progression
to decompensation of cirrhosis.27 As reduced ﬂow velocity,
plasma procoagulant imbalance and vessel-wall abnormali-
ties25 (Virchow triad) are mechanistic factors for venous
thromboembolism, it is logical to assume that some sort of
antithrombotic therapy (until recently strongly contraindi-
cated in these patients) is justiﬁed.
The question is about whether it is possible to stratify
patients based on their risk and make decisions on who
should be given prophylaxis. This could be achieved on
clinical grounds (including history of thrombosis, ﬂow veloc-
ity in the portal system, etc.), but also by exploring the
possible contribution of the blood hypercoagulability as
measured by the laboratory. Recently, it was shown that
thrombin generation measured in the presence versus the
absence of thrombomodulinwould allow to express results as
the ratio (with/without thrombomodulin) and that this ratio
is much more sensitive to detect signs of hypercoagulability
than any other coagulation test.28 This phenomenon has been
ascribed to an intrinsic resistance to the anticoagulant action
of thrombomodulin that is characteristic not only of cirrho-
sis,28 but also of other noncirrhotic conditions associatedwith
an increased risk of venous thromboembolism.29 By deﬁni-
tion, the higher the ratio the higher the hypercoagulability.
The study showed that ratios in a population of compensated
cirrhosis were higher the normal and progressed from child
A-B to C. The ratio was directly correlated with the increased
levels of factor VIII (a typical feature in cirrhosis)28 and
inversely with the decreasing levels of protein C (another
feature of cirrhosis).28 The thrombin generation (with/
without thrombomodulin) ratio was also correlated with
the ratio between factor VIII and protein C.28 Interestingly,
(activated) protein C is the inhibitor of activated FVIII, thus
making their ratio an index of hypercoagulability.
Finally, a recent study showed that in vitro supplementa-
tion of protein C in plasma from patients with cirrhosis
greatly reduces hypercoagulability.30 Hypercoagulability in
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cirrhosis was independently conﬁrmed by Lisman et al31 and
Gatt et al.32 The possibility that the thrombin generation
(with/without thrombomodulin) ratio represents an in vivo
index of hypercoagulability and therefore a thrombotic risk is
being explored. Preliminary results showed that those pa-
tients with ratios higher than the 95th percentile of the
distribution of healthy subjects have an increased risk to
develop PVT (Dr. V. Lamura, unpublished data, 2015). In
addition to the increased risk of thrombosis, hypercoagula-
bility may contribute to the progression of liver ﬁbrosis
through parenchymal extinction.33
Concluding Remarks
The concomitant reduction of the pro- and anticoagulant
drivers and the increased levels of von Willebrand factor
make cirrhosis a clinical condition characterized by a reba-
lancedglobal hemostasis, despite the fact that the coagulation
tests PT and aPTT are prolonged and that these patients are
variably thrombocytopenic. Although the PT and aPTT are
still used as predictors of bleeding and to guide transfusion
with fresh frozen plasma or prohemostatic agents, they do
not represent the coagulation mechanism that operates in
vivo. There are pathophysiological and clinical considerations
that explain this apparent paradox. Plasma in the PT or aPTT
starts to clot few seconds after activation of coagulation;
furthermore, the two tests are run in plasma in the absence of
two of the key physiological activators of the protein C and
antithrombin systems (i.e., the endothelial cell receptor,
thrombomodulin, and the heparin-like substances, located
on the surface of endothelial cells). This makes PT and aPTT to
be fully responsive to the procoagulants, but much less to the
anticoagulants. The clinical considerations that support the
unsuitability of the PT and aPTT in the cirrhosis rest on the
evidence stemming from the literature (reviewed in Tripodi
and Mannucci12) and clinical practice that the abnormalities
of the two tests are poorly associated with the occurrence of
bleeding events. It is therefore conceivable that the hemosta-
sis derangement does not account for the bleeding events that
occasionally occur in these patients.
Other conditions associated with cirrhosis (i.e., hemody-
namic alterations subsequent to portal hypertension, bacte-
rial infections, endothelial dysfunction, and renal failure)
probably play a major role in determining bleeding. Effort
to treat these conditions would probably be much more
effective in preventing or controlling bleeding than the infu-
sion of plasma or prohemostatic agents.
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